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| INTRODUCTION
Parkinson's disease is a progressive neurodegenerative disorder characterized by the widespread loss of select classes of neurons throughout the nervous system. The pathological hallmarks of sporadic Parkinson's disease are Lewy bodies and neurites: abnormal protein aggregates found in surviving nerve cell bodies and axons at sites of neurodegeneration, of which the presynaptic protein, α-synuclein, is the major constituent. [1] [2] [3] Many structures outside of the substantia nigra pars compacta (SNpc) are damaged by the disease 4 and there is now strong evidence that sporadic Parkinson's disease starts at a remote site before spreading to the SNpc. 5, 6 Putative sites of initiation are regions in the periphery connected to the brainstem, including the olfactory mucosa and gastrointestinal (GI) tract. 7 Although
Parkinson's disease is best known for its characteristic motor symptoms, non-motor symptoms impose a significant burden on quality of life. [8] [9] [10] These arise early in the course of disease and are often unresponsive to, or worsened by, dopamine-replacement therapy. 10, 11 The dominance of non-motor symptoms in the preclinical stages of disease has helped guide the quest for biomarkers that can provide an accurate diagnosis before the onset of motor symptoms. For this reason, much attention has been focused on the GI tract, which is heavily burdened by Lewy pathology 12 and commonly expresses symptoms including dysphagia, bloating and constipation. 13 Of these, constipation has been reported to manifest as early as 10 years prior to motor symptoms. 14 Curiously, accumulation of α-synuclein can occur in the gut up to 10 years prior to diagnosis. 15 The gut's putative role in the pathogenesis of Parkinson's disease and its accessibility makes it suitable for investigating mechanisms underlying disease pathogenesis and assessing efficacy of disease-modifying agents and candidate disease biomarkers. Aggregation of α-synuclein is central to these goals. Mutations in SNCA, the gene encoding α-synuclein, and gene duplications and triplications, which increase its propensity to aggregate, can cause Parkinson's disease. 16 α-Synuclein oligomers are elevated in the cerebrospinal fluid in Parkinson's disease 17, 18 and can seed the aggregation of endogenous α-synuclein in both central 19 and peripheral 20, 21 neurons. Although the mechanisms are not entirely clear, mitochondrial dysfunction and oxidative stress may contribute to aggregation of α-synuclein in Parkinson's disease. 22 There is a positive relationship between exposure to the pesticide rotenone and risk of Parkinson's disease, 23 and biochemical studies implicate a systemic defect in mitochondrial complex I. 24 Rotenone is a mitochondrial complex I inhibitor capable of replicating the classic features of
Parkinson's disease, thereby demonstrating a direct link between mitochondrial dysfunction and α-synuclein aggregation. 25, 26 Metabolic stress evoked by elevated intracellular calcium concentration provoked by raised extracellular potassium concentration can also induce α-synuclein aggregation. 27 Accordingly, the disease selectively targets highly metabolically active populations of neurons, but spares those that express high levels of calcium binding proteins.
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In this study, we used immunohistochemistry to determine whether rotenone or prolonged exposure to raised [K+] in organotypic culture triggers accumulation of α-synuclein in the cell bodies and axons of enteric neurons in the guinea-pig ileum. We used a conventional antibody against α-synuclein in addition to novel conformationspecific antibodies against α-synuclein oligomers and fibrils. 29 
| MATERIALS AND METHODS

| Guinea-pig tissue collection
Adult guinea-pigs of either sex (weight 230-400 g) were stunned
and killed by exsanguination, in a manner approved by the Animal • Here, we show that rotenone, a pesticide implicated in
| Organotypic culture
Parkinson's disease, and elevated potassium cause accumulation of α-synuclein, a key feature of Parkinson's disease, in cholinergic enteric neurons.
• Enteric cholinergic neurons may be particularly vulnera- 
| Immunohistochemistry
Preparations of myenteric plexus and longitudinal muscle, or strips of circular muscle, were cut into pieces approximately 10 mm×10 mm and incubated with antisera against different combinations of markers (Table 1) at room temperature for 2 days. Preparations were rinsed three times in PBS and incubated with secondary antisera (Table 2) for 4 hours at room temperature. After a final rinse with PBS, preparations were equilibrated with 50%, 70%, and 100% carbonate-buffered glycerol, and mounted in 100% carbonate-buffered glycerol (pH 8.6).
All antibodies were diluted in 0.1 M PBS (0.3 M NaCl) containing 0.1% sodium azide. Controls for double-labeling were performed by omitting one or more primary antibodies from the procedure, and by ensuring that all combinations of primary and secondary antisera were free of cross-reactivity.
| Antibody characterization
| Syn-O1
The Syn-O1 antibody was a monoclonal raised in mice against α-synuclein fibrils. 29 The antibody selectively binds α-synuclein oligomers and fibrils and not α-synuclein monomers on inhibition ELISA and dot blotting. 29 When α-synuclein oligomers, protofibrils, and fibrils were blotted on a nitrocellulose membrane, Syn-O1 detected all three conformations, but showed most intense immunoreactivity for fibrillar α-synuclein. 29 Preabsorption of Syn-O1 with α-synuclein fibrils completely abolished its ability to detect α-synuclein fibrils, whereas preabsorption with α-synuclein monomers had little effect on its immunoreactivity. 29 On a nitrocellulose membrane, the Syn-O1 antibody did not recognize monomers or fibrils generated from β-or γ-synuclein, or the fibrillar forms of other amyloidogenic proteins including Aβ, Tau 40 , IAPP, or ABri. 
| Syn-F2
The Syn-F2 antibody was a monoclonal raised in mice against α-synuclein fibrils. 29 The antibody selectively binds α-synuclein fibrils and not α-synuclein monomers on inhibition ELISA and dot blotting.
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When α-synuclein oligomers, protofibrils and fibrils were blotted on a nitrocellulose membrane, Syn-F2 did not detect oligomers, had low immunoreactivity for protofibrils, but showed strong immunoreactivity for fibrillar α-synuclein. 29 Preabsorption of Syn-F2 with α-synuclein fibrils completely abolished its ability to detect α-synuclein fibrils, whereas preabsorption with α-synuclein monomers had little effect on its immunoreactivity. 29 On a nitrocellulose membrane, the We quantified nerve cell bodies and abnormally large varicosities labeled by the conventional antibody against α-synuclein as follows.
Images In preparations that had not been labeled with antisera, dim, autofluorescent nerve cell bodies could be detected under all filter combinations (AMCA, FITC, Cy3, and Cy5). However, these were most prominent under the FITC filter set. When these preparations were subsequently labeled with antisera for ChAT (Cy5 fluorophore) and nitric oxide synthase (NOS; Cy3 fluorophore), this autofluorescence could no longer be detected in either Cy3 or Cy5 channels, presumable because labeling increased the background and swamped the dim autofluorescent signal. However, the autofluorescence remained visible in the FITC channel. This made it possible to determine the presence of ChAT-and NOS-immunoreactivity in autofluorescent nerve cell bodies. We also examined fresh-fixed and preparations cultured for 1, 2, 3, and 4 days of culture with antisera against tyrosine hydroxylase (TH), a marker of noradrenergic and dopaminergic neurons.
Data collected from varicosity and cell body counts were rescaled for each animal using the following equation:
, where x′ is the normalized value, x is the original count, min (x) is the minimum value counted for that animal, and max (x) is the maximum value counted for that animal. The mean number of cell bodies or varicosities immunoreactive for a particular marker was calculated by generating an average of the normalized counts generated from each of the four animals. Group data were expressed as percentage means±SEM,
with n referring to the number of animals. The average total number of autofluorescent cell bodies was expressed as the mean of the total number of cells±SEM, with n referring to the number of animals.
F I G U R E 1 Micrographs of the guineapig ileum tertiary plexus labeled with antisera against α-synuclein after being fixed immediately following removal from the animal (A) or organotypic culture in a standard medium for 2 days (B), medium containing 10 mM KCl for 2 days (C), or 10 μm rotenone for 2 days (D). When the tissue was fixed immediately after removal from the animal, abnormally large α-synuclein varicosities were not identified in the tertiary plexus. However, after culture in rotenone and 10 mM KCl, abnormally large α-synuclein varicosities, as indicated by arrows, could be identified in the tertiary plexus, scale bars = 20 μm
T A B L E 3 Mean area of normal and abnormally large a-synuclein varicosities in the tertiary plexus after various conditions of culture of different duration (n=4)
Normal varicosities Abnormally large varicosities
Mean area±SEM 0.21±0.0 μm
Fluorescence micrographs were prepared with Adobe Photoshop CS5 (San Jose, CA, USA). Figures were generated from grayscale images adjusted for contrast and brightness and were cropped and resized, but no other digital processing was used. 
| Statistical analysis
| RESULTS
| Accumulation of α-synuclein in axons and cell bodies during organotypic culture
The tertiary plexus contains the axons of inhibitory nitrergic motorneurons and more abundant excitatory cholinergic motorneurons, which supply the overlying longitudinal muscle layers. Previous studies have shown that α-synuclein is expressed in the axons of all cholinergic motorneurons, identifiable by immunoreactivity for vesicular acetylcholine transporter (VAChT), and is not expressed in the axons of nitrergic motorneurons, identified by immunoreactivity for NOS. 31 When guinea-pig ileum was maintained in organ culture, a number of abnormally large varicosities were visible in the tertiary plexus after immunolabeling with the conventional antibody against α-synuclein (Fig. 1) . On average, their surface area was seven times greater than that of randomly sampled normal varicosities (Table 3 ).
An observer, blinded to the tissue treatment, quantified these abnormally large varicosities in tertiary plexus labeled by the conventional F I G U R E 3 Micrographs of the myenteric plexus or tertiary plexus after culture in standard medium for 1, 2 or 4 days that has been labeled with antisera against Syn-F2. After 1 and 2 days in culture (A and B, respectively), varicosities immunoreactive for Syn-F2 were not identified in the myenteric plexus. However, after 4 days (C), in 1 of 4 preparations, Syn-F2-IR varicosities were present. Varicosities immunoreactive for Syn-F2 were not identified in the tertiary plexus after 1 (D), 2 (E), or 4 (F) days of culture, scale bars = 20 μm
α-synuclein antibody, from preparations cultured in each of the four solutions (Table 4) . Total numbers of abnormally large α-synuclein varicosities varied considerably but they were consistently absent in all preparations that were fixed immediately after removal from the animal. Large varicosities were seen in all preparations subjected to organ culture, including those in standard DME/F12 medium without either rotenone or KCl. In most cases, large varicosities appeared by day 1, reached peak numbers by day 2, and reduced again by day 4 (Table 4 ). With 10 μM rotenone, the peak number of large varicosities in the tertiary plexus appeared at day 4, but this did not reach significance (P>.05 in all instances, f = 2.624, df = 11). Similar abnormally large α-synuclein varicosities were also visible in the circular muscle and probably in the myenteric plexus, but could not be quantified for technical reasons. This suggests that the process of maintaining tissue in organ culture causes a small subset of varicosities to swell significantly, and this was not significantly affected by either rotenone or raised KCl.
Using the same conventional antibody to α-synuclein, we have previously reported that α-synuclein-immunoreactivity is not detectable in myenteric nerve cell bodies of the guinea-pig ileum fixed immediately after removal from the animal, 31 although it is abundant in axons. This was confirmed in the present study and extended by the observation that no detectable accumulation of α-synuclein was detectable in enteric nerve cell bodies after 1-4 days of organ culture in 
| Characterization of antibodies against α-synuclein oligomers and fibrils
Aggregation of α-synuclein in nerve terminals and cell bodies is strongly implicated in the pathogenesis of Parkinson's disease. We used novel conformation-specific antibodies against α-synuclein fibrils and oligomers to detect these species in guinea-pig myenteric neurons after organotypic culture with and without rotenone and KCl. 29 Control preparations of myenteric plexus were fixed immediately after removal from the animal and then processed for immunohistochemistry with a range of concentrations of antisera to α-synuclein fibrils (Syn-F2) and α-synuclein oligomers (Syn-O1). Both antibodies produced labeling of varicosities in myenteric ganglia, internodal strands, circular muscle plexus, and tertiary plexus, but did not label enteric nerve cell bodies or inter-varicose fibers (Fig. 2 ).
This pattern was identical to previous reports using the conventional antibody to α-synuclein. 28 We then identified a dilution threshold, below which labeling of varicosities in fresh-fixed tissue disappeared.
The threshold dilution for these antibodies was: Syn-F2 (1:200) and Syn-O1 (1:1500). These threshold dilutions were then used to identify whether expression levels of their specific antigens (oligomers or fibrils) had increased above baseline under different conditions of organotypic culture.
F I G U R E 5
Micrographs of the myenteric plexus or tertiary plexus after culture in medium containing 10 μm rotenone for 1, 2, or 4 days that has been labeled with antisera against Syn-F2. After 1 day culture, there were scant Syn-F2-IR varicosities in the myenteric plexus (A). The density of labeling of these varicosities increased over the subsequent 2 (B) and 4 (C) days in culture. The same was true of labeling for Syn-F2 in the tertiary plexus; Syn-F2-IR varicosities were present after 1 day in culture (D), but increased in density over the subsequent 2 (E) and 4 (F) days in culture, scale bars = 20 μm
| Accumulation of α-synuclein fibrils in axons during organotypic culture
α-Synuclein fibrils could not be detected in axons or cell bodies in the myenteric plexus, tertiary plexus, or circular muscle plexus in fresh-fixed preparations, using Syn-F2 at the threshold concentration of 1:200. Nor was labeling detectable after 1 and 2 days culture in standard DME/F12 medium (Fig. 3) . After 4 days of culture very weak and diffuse labeling was detected in the tertiary plexus in 1 of 4 preparations (Fig. 3) . In contrast, in DME/F12 culture medium with 1 μM rotenone (Fig. 4) , 10 μM rotenone (Fig. 5) , or 10 mM KCl (Fig. 6 ), α-synuclein fibrils could be readily detected in axons in the myenteric plexus, tertiary plexus, and circular muscle plexus in four of four preparations at 1, 2, and 4 days. In the first 2 days, α-synuclein fibrils were more abundant in the tertiary plexus than in the myenteric plexus, but by 4 days this difference had disappeared (Figs 4-6 ). No accumulation of α-synuclein fibrils in myenteric nerve cell bodies was detected under any of the conditions tested. 
| Accumulation of α-synuclein oligomers in axons during organotypic culture
| Autofluorescent cell bodies in the myenteric plexus during organotypic culture
Faintly autofluorescent nerve cell bodies could be detected in some preparations that had been maintained in organ culture, but not in fresh-fixed preparations. They were visible in all filter sets (Cy3, Cy5, FITC, and AMCA), but most readily identified in the FITC filter set (Fig. 11) . In unlabeled preparations, cultured under the four different conditions for 1-4 days, a blinded observer randomly selected 20 myenteric ganglia and quantified autofluorescent cell bodies. The highest number was counted in tissue exposed to 10 μM rotenone after 4 days of culture (Table 5) , with similar proportions identified in specimens cultured for 2 and 4 days with 1 μM rotenone (Table 5 ). Autofluorescent cell bodies were clustered in ganglia, with some ganglia containing none, and others containing 10 or more. Autofluorescent cell bodies were too infrequent to count accurately in preparations cultured in standard DME/F12 medium or in medium containing 10 mM KCl (see Table 5 ), but small numbers were present when actively sought out, which could be targeted for subsequent immunohistochemical labeling -see below (Table 6 ).
F I G U R E 7
Micrographs of the myenteric plexus or tertiary plexus after culture in standard medium for 1, 2, or 4 days that has been labeled with antisera against Syn-O1. Varicosities immunoreactive for Syn-O1 were not identified in the myenteric plexus after 1 (A), 2 (B), or 4 (C) days in culture. The same was true of labeling for Syn-O1 in the tertiary plexus after 1 (D), 2 (E), and 4 (F) days in culture, scale bars = 20 μm
| Neurochemical coding of autofluorescent cell bodies after organotypic culture
In the present study, preparations labeled with antisera against NOS and ChAT were subsequently visualized with secondary antibodies conjugated to Cy3 and Cy5 respectively. As described in the methods section, autofluorescent nerve cell bodies were clearly visible using FITC filters (Fig. 11 ) and in unstained preparations in Cy3 and Cy5 filters. However, the autofluorescent signal did not appear to break through into Cy3 and Cy5 channels after NOS and ChAT immunolabeling, presumably because the dim autofluorescent signal was overwhelmed by the background NOS or
ChAT immunofluorescence. This allowed us to identify whether autofluorescent nerve cell bodies were immunoreactive for ChAT and/ or NOS (Table 6 ). In all preparations analysed, autofluorescent cell bodies were either ChAT + /NOS − or ChAT − /NOS − ( (Table 7) . No NOS-IR neurons were autofluorescent. 
| Tyrosine hydroxylase immunoreactivity in the myenteric plexus of fresh fixed and cultured guinea pig ileum
In tissue fixed immediately after removal from the animal and labeled for TH immunoreactivity, numerous intensely labeled varicose axons were visible in the myenteric plexus. However, no TH-IR nerve cell bodies were identified. After 1 day of culture, TH-IR varicose fibers were still abundant in myenteric plexus, but by day 2, their density was greatly reduced. By day 4, TH-IR varicose fibers were very sparse; the few remaining axons were typically swollen and fragmented (Fig. 14A-C) . TH-immunoreactivity was detected in one enteric nerve cell body in these preparations, representing considerably less than 0.1% of enteric neurons in the preparations (Fig. 14D) . Thus, nearly all TH-immunoreactivity in the myenteric plexus of guinea pig ileum is in the axons of ex- 
F I G U R E 9
Micrographs of the myenteric plexus or tertiary plexus after culture in medium containing 10 μm rotenone for 1, 2 or 4 days that has been labeled with antisera against Syn-O1. Varicosities immunoreactive for Syn-O1 were not identified in the myenteric plexus after 1 (A), 2 (B), or 4 (C) days in culture.
The same was true of labeling for Syn-O1 in the tertiary plexus after 1 (D), 2 (E), and 4 (F) days in culture. Scale bars = 20 μm
| DISCUSSION
α-Synuclein is a neuronal protein localized to presynaptic terminals that normally exists as an unfolded, aggregation-prone, monomer or as a stable, aggregation-resistant tetramer with a rich α-helix conformation. 32 These tetramers differ from the pathological oligomers.
Oligomers are intermediates to the α-synuclein fibrils which are the major component of Lewy pathology, which vary in size and have a β-sheet conformation. 33 A variety of α-synuclein species have been identified in Lewy pathology, including truncated fragments, those modified by oxidation, nitration, phosphorylation, and ubiquitylation, and those having undergone various stages of aggregation. 34 Thus, there may be multiple intermediates in the formation of mature synuclein fibrils. Conventional α-synuclein antibodies do not distinguish α-synuclein species; therefore, conformation-specific antibodies are required to detect specific pathological features of Parkinson's disease.
In this study, we used three α-synuclein antisera to detect changes in α-synuclein expression in enteric neurons following rotenone exposure or raised KCl concentration in ex vivo segments of guinea-pig ileum. Our conventional α-synuclein antibody that detects monomers, oligomers, and fibrils did not distinguish any morphological abnormalities in α-synuclein form or distribution caused by rotenone or
KCl. In contrast, the conformation-specific Syn-F2 showed increased whereas nearly all cholinergic neurons do. 35 The effects of KCl may be mediated by increased neural excitability and we speculate that this may increase expression of α-synuclein fibrils, although the mechanism is uncertain.
| Accumulation of α-synuclein in enteric neurons after organotypic culture
Pathological α-synuclein species have recently been reported in the GI tract of patients with Parkinson's disease, but not in age-matched healthy controls. 36, 37 However, "pathological" α-synuclein species have been detected in the gut of healthy asymptomatic aging adults. [38] [39] [40] [41] Early studies of the GI tract in Parkinson's disease reported Lewy bodies and neurites comparable to those observed in brain. [42] [43] [44] Animal studies have reported morphological changes in α-synuclein localization in the enteric nervous system of mice expressing SNCA mutants associated with Parkinson's disease, [45] [46] [47] and after exposure but an increase was seen in the jejunum, 48 duodenum, and ileum. 53 Another study reported an initial decrease, followed at 6 months by an increase in α-synuclein. 49 The present study used concentrations of rotenone and durations of exposure reported to cause α-synuclein accumulation and nerve cell death in brain slices, 54,55 albeit higher than required to cause the first signs of nigrostriatal degeneration. shown that α-synuclein and VAChT are highly co-expressed in varicosities in the guinea pig ileum and rectum. 31, 35 Although α-synuclein is also expressed with other neurochemical markers, such as 5-HT, somatostatin, and many others, expression correlated most closely with VAChT; indeed, the proportions of varicosities expressing α-synuclein were almost identical to the proportions expressing VAChT. 35 These effects occurred although the conventional α-synuclein antiserum did not detect any overall morphological changes.
No accumulation of α-synuclein oligomers was detected with a conformation-specific antiserum under the same conditions. The Syn-F2 and Syn-O1 antibodies do not recognize the same epitopes. 29 The 
| Rotenone causes necrosis of cholinergic enteric neurons
Exposure to rotenone evoked autofluorescence in many nerve cell bodies, consistent with ongoing necrosis. [65] [66] [67] [68] Over 80% of these cell bodies were immunoreactive for the cholinergic marker, ChAT.
The remainder lacked both ChAT-and NOS-immunoreactivity.
Cholinergic neurons comprise from 68% to 81% of myenteric neurons in guinea pig small intestine, 69, 70 and α-synuclein is restricted to cholinergic neurons in this same preparation. 35 What is most striking about these figures is that none of the autofluorescent cells was immunoreactive for NOS, despite NOS being present in 20-25% of myenteric neurons in guinea pig ileum. 71 Together, ChAT and NOS account for ~99% of nerve cell bodies in the myenteric plexus at this site. 71 Cholinergic neurons can be further subdivided on the basis of co-existence of 5-HT, somatostatin, substance P, calretinin and calbindin and other markers. 71 Our results suggest either that NOScontaining neurons are resistant to rotenone-induced necrosis, or that NOS-immunoreactivity is lost from necrotic nerve cells. If rotenone's toxicity is mediated through aggregation of α-synuclein, then this may explain the selective loss of cholinergic neurons in our preparation, as nitrergic neurons do not express α-synuclein. 35, 72 Nitric oxide synthase may have a neuroprotective effect on enteric neurons in inflammation 73 and ischemia/reperfusion. 74 Reactive oxygen species are produced in ischemia/reperfusion 75 ; it is possible that NOScontaining neurons have higher levels of endogenous antioxidants to cope with reactive oxygen species and reactive nitrogen species during nitric oxide synthesis. 
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